Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct 23;10(1):167.
doi: 10.1186/s13045-017-0536-6.

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer

Yi-Chen Zhang  1 , Qing Zhou  1 , Yi-Long Wu  2
Affiliations
Review

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer

Yi-Chen Zhang et al. J Hematol Oncol. .

Abstract

The treatment paradigm of non-small cell lung cancer (NSCLC) has evolved into oncogene-directed precision medicine. Identifying actionable genomic alterations is the initial step towards precision medicine. An important scientific progress in molecular profiling of NSCLC over the past decade is the shift from the traditional piecemeal fashion to massively parallel sequencing with the use of next-generation sequencing (NGS). Another technical advance is the development of liquid biopsy with great potential in providing a dynamic and comprehensive genomic profiling of NSCLC in a minimally invasive manner. The integration of NGS with liquid biopsy has been demonstrated to play emerging roles in genomic profiling of NSCLC by increasing evidences. This review summarized the potential applications of NGS-based liquid biopsy in the diagnosis and treatment of NSCLC including identifying actionable genomic alterations, tracking spatiotemporal tumor evolution, dynamically monitoring response and resistance to targeted therapies, and diagnostic value in early-stage NSCLC, and discussed emerging challenges to overcome in order to facilitate clinical translation in future.

Keywords: Liquid biopsy; Next-generation sequencing; ctDNA.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This is not applicable for this review.

Consent for publication

This is not applicable for this review.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Integration of NGS and liquid biopsy maximizes overall advantages
Fig. 2
Fig. 2
Current applications and future development of NGS-based liquid biopsy in lung cancer
See this image and copyright information in PMC

References

    1. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23–28. doi: 10.1126/science.959840. - DOI - PubMed
    1. MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol. 2013;31:1815–1824. doi: 10.1200/JCO.2012.46.5948. - DOI - PMC - PubMed
    1. Green P. Against a whole-genome shotgun. Genome Res. 1997;7:410–417. doi: 10.1101/gr.7.5.410. - DOI - PubMed
    1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921. doi: 10.1038/35057062. - DOI - PubMed
    1. Evans JP. The Human Genome Project at 10 years: a teachable moment. Genet Med. 2010;12:477. doi: 10.1097/GIM.0b013e3181ef16b6. - DOI - PubMed

Publication types

MeSH terms